In vitro study reveals that non-cytotoxic doses of 2-DG hamper cell invasion in aggressive breast cancer, suggesting potential utility as an adjuvant therapy with reduced side effects.
Hyper-glycolytic phenotype of invading cells caters to rapid energy production required for invasion while TCA cycle/ETC cater to cellular energy needs for sustenance in aggressive BC. Lower, non-cytotoxic doses of 2-DG can hamper invasion and can potentially be used as an adjuvant with other anti-cancer therapies without the usual side-effects associated with cytotoxic doses.
No takes yet. Share an insight, caveat, or question.
Fujita et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: